Zevra therapeutics to acquire acer therapeutics, expanding its rare disease portfolio and adding commercial product

Proposed acquisition of acer for $15m in zevra stock plus contingent value rights (cvrs) and zevra's purchase of acer's secured debt in capital efficient structure

ZVRA Ratings Summary

ZVRA Quant Ranking